KRAS Gene Mutations and Gender Differences in Colorectal Cancer

Oleg I. Kit, PhD, ScD; Dmitriy I. Vodolazhskiy, PhD, Yuriy A. Gevorkyan, PhD, ScD; Natalia V. Soldatkina. PhD, ScD*

Federal State Budget Institution «Rostov Research Oncologic Institute», Rostov-on-Don, the Russian Federation

*Corresponding author: Natalia V. Soldatkina. PhD, Rostov Research Oncological Institute Rostov-on-Don, the Russian Federation. E-mail: snv-rnioi@yandex.ru

Published: March 25, 2015. DOI: 10.21103/Article5(1)_CR2

Abstract: 

The aim of this study was to investigate the frequency and spectrum of KRAS mutations in men and women with colorectal cancer (CRC), and an impact of KRAS-mutation status on the clinical and morphological features of CRC. The study included 303 patients (168/55.4% women and 135/44.6% men) with CRC T2-4N0-2M0-1. We defined 7 KRAS SNP-mutations (G12D, G12A, G12R, G12C, G12S, G12V and G13D) located within codons 12 and 13 using Bio-Rad real-time thermal cyclers CFX96 and Real-Time-PCR- KRAS-7M Kit. The frequency of KRAS mutations was 35.6% in the CRC patients with a predominant presence of G>A transitions. The KRAS codon 12 and 13 mutations are predictive of poor prognosis The KRAS-mutated CRC has clinical features in view of the gender differences. KRAS-mutation status is a promising predictive biomarker of personalized treatment.

Keywords: 
KRAS codon 12 and 13 mutations; colorectal cancer; gender differences.
References: 
  1. Chissov VI, Starinskiy VV, Petrova GV. Malignancies in Russia in 2011 (morbidity and mortality). M.: FSBI "MORI n.a. P.A. Herzen” of Ministry of Healthcare of RF; 2013.
  2. Kit OI. The problem of colorectal cancer in the early twenty-first century: achievements and perspectives. Rus J Gastroenterology, Hepatology, Coloproctology 2013; 3(23):65-71.
  3. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18(16):2938-47.
  4. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 2000; 355(9209):1041-7.
  5. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22(1):23-30.
  6. Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26(12):2013-9.
  7. Lièvre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, et al. KRAS Mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26(3):374-9.
  8. Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23(9):1803–10.
  9. Sartore-Bianchi A, Moroni M, Veronese S, Carnaghi C, Bajetta E, Luppi G, et al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 2007; 25(22):3238–45.
  10. Janakiraman M, Vakiani E, Zeng Z, Pratilas CA, Taylor BS, Chitale D, et al. Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res 2010; 70(14): 5901–11.
  11. Vigil D, Cherfils J, Rossman KL, Der CJ. Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? Nat Rev Cancer 2010; 10(12):842–57.
  12. Smit VT, Boot AJ, Smits AM, Fleuren GJ, Cornelisse CJ, Bos JL. KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res 1988; 16(16):7773–82.
  13. Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359(17):1757–65.
  14. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol  2008;26(10):1626–34.
  15. Van Cutsem E, Köhne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol  2011; 29(15):2011–9.
  16. Neumann J, Zeindl-Eberhart E, Kirchner T, Jung A. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract  2009; 205(12):858–62.
  17.  Bos JL. Ras oncogenes in human cancer: a review. Cancer Res 1989;49(17):4682–9.
  18.  Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007; 7(4):295–308.
  19. Tan C, Du X. KRAS mutation testing in metastatic colorectal cancer. World J Gastroenterol 2012; 18(37):5171-80.
  20. Vodolazhskiy DI, Kit OA, Gevorgyan YuA, Soldatkina NV.  Features of KRAS mutation in advanced colorectal cancer. Eurasian J Oncol 2014; 3(3):82-4.
  21. Phipps AI, Buchanan DD, Makar KW, Win AK, Baron JA, Lindor NM, et al. KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers. Br J Cancer 2013; 108(8):1757-64

The fully formatted PDF version is available.       

Download Article

Int J Biomed. 2015; 5(1):11-15. © 2015 International Medical Research and Development Corporation. All rights reserved.